RxDoctor Payments Data

Teresa Chan, MD

Family Medicine · New York, NYNPI 1922190388

Payments from drug & device makers

$1,681in general payments, 2019–2025

Across 86 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$477
  • Lilly USA, LLC$189
  • Sanofi-aventis U.S. LLC$183
  • Gilead$141
  • Merck$124
  • Avion Pharmaceuticals$119
  • plus $449 from 7 others

What the payments were for

  • Food & beverage$1,66399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,681 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$38,288
Medicare patients
34
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$43,026
OzempicSemaglutide19$26,933
JanumetSitagliptin Phos/Metformin Hcl12$19,533
VemlidyTenofovir Alafenamide13$18,844
VascepaIcosapent Ethyl31$17,858
EliquisApixaban14$17,714
Nurtec OdtRimegepant Sulfate12$12,125
RestasisCyclosporine14$9,036
LicartDiclofenac Epolamine12$8,535
JanuviaSitagliptin Phosphate12$5,967
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,513
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl13$2,648
Rosuvastatin Calcium155$1,881
Lidocaine25$1,685
Novolog FlexpenInsulin Aspart11$1,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia$124$25,50024 claims
GileadVemlidy$141$18,84413 claims
AbbVieRestasis$57$9,03614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →